Less than a year after moving to Boston, diabetes-focused Intarcia raises $200M

Kurt Graves, CEO of Boston-based drug developer Intarcia Therapeutics, knows how rare it is for an 80-employee biotech to be running a late-stage drug trial in a disease as widespread as type 2 diabetes...